Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.71 +0.46 (+0.88%)

Delayed Quote Updated: 3:40 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

38 39 Next >

While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer ↗

December 05, 2023

Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in...

Via Benzinga

Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation ↗

December 05, 2023

Roche Holdings AG (OTC: RHHBY) announced results from the Phase 3 INAVO120 study of the investigational therapy, inavolisib, in combination with palbociclib (Ibrance) and fulvestrant as a potenti

Via Benzinga

Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

December 05, 2023

From Genentech

Via Business Wire

Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative ↗

December 04, 2023

Via Benzinga

Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker ↗

December 04, 2023

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs. Roche stock gained on the news.

Via Investor's Business Daily

Roche Joins Bandwagon To Challenge Novo Nordisk, Eli Lilly For Weight Loss Drugs ↗

December 04, 2023

Roche Holding AG (OTC: RHHBY) has agreed to

Via Benzinga

AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report ↗

December 04, 2023

AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...

Via Benzinga

Topics Artificial Intelligence

Ignore Crypto: These Stocks Could Make You Rich ↗

November 23, 2023

Investing in solid, growing businesses is a less risky road to riches than investing in Bitcoin or other cryptocurrencies.

Via The Motley Fool

Genentech and NVIDIA Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development

November 21, 2023

From Genentech

Via Business Wire

Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare ↗

November 17, 2023

Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.

Via InvestorPlace

FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca ↗

November 16, 2023

The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small

Via Benzinga

Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030

November 14, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NYSE:BMY),(NYSE:NVS),(NYSE:MRK),(OTCQX:RHHBY) EQNX::TICKER_END

Via FinancialNewsMedia

The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? ↗

November 10, 2023

The real competitive battle is about to begin, and it will last a long time.

Via The Motley Fool

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake ↗

November 07, 2023

The company's recently FDA-approved gene therapy is struggling to gain traction.

Via Investor's Business Daily

Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug ↗

November 02, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate

Via Benzinga

Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks ↗

October 31, 2023

Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...

Via Benzinga

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars? ↗

October 28, 2023

The three companies are spending big on IBD therapies.

Via The Motley Fool

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

October 27, 2023

From Genentech

Via Business Wire

It's Hard to Be a Biotech Bull in This Market, but This Stock Is a Buy ↗

October 24, 2023

The market's dour reaction to Roivant Sciences' latest deal doesn't add up.

Via The Motley Fool

Why Is Roivant Sciences (ROIV) Stock Up Today? ↗

October 23, 2023

ROIV stock barely moved after the Roche deal, reflecting a down market and lack of movement on Roivant's other drug candidates.

Via InvestorPlace

Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise

October 23, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END

Via FinancialNewsMedia

Roche Spends $7.1 Billion On Roivant Drug, Following Merck, Sanofi Into The Raging Hot Immunology Space ↗

October 23, 2023

Roche is joining Merck and Sanofi in the TL1A drug space. These drugs could treat stomach diseases.

Via Investor's Business Daily

Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal ↗

October 23, 2023

Roche Holding AG (OTC: RHHBY) inked a deal to acquire

Via Benzinga

Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant

October 23, 2023

From Roivant Sciences

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance ↗

October 19, 2023

The company's third-quarter sales also declined and came in light.

Via Investor's Business Daily

Roche Reports Nine Months Sales Growth Despite Lower Sales From COVID-19 Products ↗

October 19, 2023

Roche Holdings AG's (OTC: RHHBY) nine months

Via Benzinga

Genentech’s Alecensa Reduces the Risk of Disease Recurrence or Death by an Unprecedented 76% in People With ALK-Positive Early-Stage Non-Small Cell Lung Cancer

October 18, 2023

From Genentech

Via Business Wire

What's Going On Cancer Player Monte Rosa Therapeutics Stock Today? ↗

October 17, 2023

Monte Rosa Therapeutics Inc (NASDAQ: GLUE) entered into a strategic collaboration and licensing agreement with Roche Holdings AG (OTC:

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.